RecruitingPhase 4NCT05095857

The Anaesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury

S-ketamine for Cortical Spreading Depolarisation in Patients With Severe Acute Brain Injury


Sponsor

Rigshospitalet, Denmark

Enrollment

400 participants

Start Date

Sep 15, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Cortical spreading depolarisations are pathological depolarisation waves that occur frequently after severe acute brain injury and has been associated with poor outcome. S-ketamine has been shown to inhibit cortical spreading depolarisations. The aim of the present study is to examine the efficacy and safety of using S-ketamine for treatment of patients with severe acute brain injury, as well as the feasibility of the trial design.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Age ≥ 18 years.
  • Admitted to the NICU with a diagnosis of traumatic brain injury (TBI), aneurysmal subarachnoid haemorrhage (aSAH) or spontaneous intracerebral haemorrhage (ICH).
  • Planned for surgery with a supratentorial craniotomy or craniectomy.
  • Expected to continue sedation and mechanical ventilation after surgery.

Exclusion Criteria9

  • Neither patient or next of kin understand Danish or English.
  • Known allergy to S-ketamine (the active pharmaceutical ingredient or the excipients).
  • Wake-up call to occur immediately after surgery.
  • Pregnancy (all female participants aged ≤ 50 years will have a urine or blood hCG taken to control for pregnancy).
  • Active anti-psychotic treatment before admission.
  • Current abuse of ketamine.
  • Decision to withdraw active treatment.
  • ICH secondary to a known brain tumour at the time of inclusion.
  • Since this is an emergency trial informed consent will be obtained from a trial guardian before inclusion of the participant, and informed consent will be sought from next of kin as soon as possible.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGS-ketamine

S-ketamines is an NMDA-receptor antagonist with sedative and analgesic properties. It will in the present trial be given in sedative doses (2-3 mg/kg/hour) in case of clustered SDs following a dosing algorithm according to SD occurrence.

OTHERIsotonic saline (placebo)

Isotonic saline has the same appearance as S-ketamine with both being clear liquids with no bubbles or other distinguishing features.


Locations(1)

Rigshospitalet

Copenhagen, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05095857


Related Trials